Navigation Links
Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services
Date:6/21/2013

emical Medience Corporation
Mitsubishi Chemical Medience Corporation is a member of the Mitsubishi Chemical Holdings Corporation Group, which is headquartered in Tokyo, Japan. Mitsubishi Chemical Medience is the first company in Japan to establish a business style that combines clinical and diagnostic laboratory testing services with in vitro diagnostics (IVD) and pharmaceutical development support. One of Mitsubishi Chemical Medience's primary business areas is their IVD business, which includes the development, sale, export, and import of in vitro diagnostic reagents and instruments. Mitsubishi Chemical Medience's globally accepted PATHFAST system, a rapid point-of-care immunochemistry analyzer, has been exported to more than 40 countries. Throughout almost five decades of IVD business, customers in various chemical and diagnostic industry segments have come to trust and rely on Mitsubishi Chemical Medience's competence and strength, as represented by the superior quality of their products and customized solutions. To learn more, visit the company's website at http://www.medience.co.jp/english/index.html.


'/>"/>
SOURCE Mitsubishi Chemical Medience Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
2. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
3. ChemAxon Announces New Version of chemicalize.org for Tablet PCs
4. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
5. DOW Chemical at the World Drug Delivery & Formulation Summit 2013
6. Top Insight On Green Chemistry, API Manufacturing, Specialty Chemicals And Supply Chain Management At InformEx USA
7. InformEx Platforms Top Chemical Suppliers In The Specialty, Industrial & Pharmaceutical Ingredients Markets
8. US Animal Health Chemicals Market
9. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
10. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
11. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Critical Care, a LifeCentre partner practice, located at 165 Fort Evans ... in Loudoun County to receive a small ... Barnes , Medical Director, is a well-seasoned veterinarian of more than ... are avid scuba divers. "As altitude skiers and hikers, we recognize ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... WIRE via COMTEX News Network),-- Endo Pharmaceuticals ... Holdings Inc. (NASDAQ: ENDP), has presented results,from ... evaluating Frova (frovatriptan succinate) 2.5 mg,tablets as ... menstrual migraine (MM). The data demonstrated,that FROVA ...
... SALT LAKE CITY, UT, June 11, 2007 ... Genetics, Inc. (NASDAQ: MYGN) (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ... comparison of a,"Staggered Start" and a "Randomized ... Staggered Start" clinical trial,design at the Alzheimer's ...
Cached Medicine Technology:Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... ... Gary S. Berger MD today reported the results of the largest ... prospective study concludes that tubal ligation reversal is more successful than IVF ... of the study interval, over 60 percent of the tubal reversal patients ...
... ... supplier, Dynamic Computer Corporation, partners with AiRISTA to provide Wi-Fi-based RFID solutions. ... Sparks, ... agreement with Dynamic Computer Corporation (DCC) to promote, distribute, implement and support AiRISTA,s ...
... patient,s likelihood of survival. That is the finding of ... of Cancer , a peer-reviewed journal of the ... systematic screening of psychological distress and subsequent treatments. ... attitudes can impact their physical health. To determine the ...
... than standard medicines , SUNDAY, Sept. 13 (HealthDay News) ... pressure cannot be controlled by existing medications has done ... reductions in blood pressure were achieved with various doses ... hypertensive despite trying three or more medications, said a ...
... YORK, NY, Sept. 13 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - ... acquires, and develops novel drug targets that disrupt the ... appointed Dr. Philip Gould as a Member Designate of ... contribute his career experience in multinational blue chip drug ...
... ... High Point Solutions has been awarded the prestigious Gold certification from ... and specialization. The Certification recognizes High Point,s expert level of ... Unified Communication, and Data Center. Gold Certified Partners are considered extensions ...
Cached Medicine News:Health News:Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation 2Health News:AiRISTA's Unified Visibility Solutions Bringing Together Wi-Fi RTLS, And Telemetry Offer Enormous Business Opportunities To Systems Integrators 2Health News:Depression increases cancer patients' risk of dying 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3Health News:GENova appoints Dr. Philip Gould to Scientific Advisory Board 2Health News:GENova appoints Dr. Philip Gould to Scientific Advisory Board 3Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: